Canine intrahepatic portosystemic shunt insertion into the systemic circulation is commonly through primary hepatic veins as assessed with CT angiography

Congenital intrahepatic portosystemic shunts (IHPSS) in dogs are traditionally classified as right, left, or central divisional. There are few descriptive studies regarding the variation of IHPSS within these categories. This multicenter, analytical, cross‐sectional study aimed to describe a large series of dogs with CT angiography (CTA) of IHPSS, hypothesizing that there would be variation to the existing classification. Ninety CTA studies were assessed for IHPSS type, insertion, and the relationship of the insertion to the primary hepatic veins. Ninety‐two percent of IHPSS inserted into a primary hepatic vein (HV) or phrenic vein, 8% inserted directly into the ventral aspect of the intrahepatic caudal vena cava. The most common IHPSS type was a single right divisional (44%), including those inserting via the right lateral HV or the caudate HV. Left divisional IHPSS (33%) inserted into the left HV or left phrenic vein. Central divisional IHPSS (13%) inserted into the quadrate HV, central HV, dorsal right medial HV, or directly into the ventral aspect of the intrahepatic caudal vena cava. Multiple sites of insertion were seen in 9% of dogs. Within left, central, and right divisional types, further subclassifications can therefore commonly be defined based on the hepatic veins with which the shunting vessel communicates. Relating IHPSS morphology to the receiving primary HV could make IHPSS categorization more consistent and may influence the type and method of IHPSS attenuation recommended

Flight with lift modulation inside a planetary atmosphere

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/76287/1/AIAA-7461-486.pd

Owyhee Russet: AVariety with High Yields of U.S. No. 1 Tubers, Excellent Processing Quality, and Moderate Resistance to Fusarium Dry Rot (\u3ci\u3eFusarium solani var. coeruleum\u3c/i\u3e)

Owyhee Russet (AO96160-3) originated from a cross between A89384-10 and A89512-3 in 1996. Owyhee Russet was released in 2009 by Oregon State University, in cooperation with the USDA-ARS and the Agricultural Experiment Stations of Idaho and Washington and is a product of the Northwest Potato Variety (Tri-State) Development Program. Owyhee Russet has semi-erect medium sized vines with medium to late maturity. The tubers are long, with a tan skin, medium russeting, and attractive tuber appearance for fresh market. Owyhee Russet was evaluated in several locations across the Northwest for more than 15 years. Total yield of Owyhee Russet is similar to that of Russet Burbank and Ranger Russet but significantly higher than Russet Norkotah. U.S. No.1 tuber yield of Owyhee Russet is significantly higher than Russet Burbank and Russet Norkotah, resulting in substantially higher marketable yield. Owyhee Russet tubers have significantly higher specific gravity than Russet Burbank and Russet Norkotah. Fry color following tuber storage at 4°C and 9°C is significantly lighter for Owyhee Russet than the comparison varieties. Relative strengths include high yield with a very high proportion of U.S. No.1 tubers, good tuber appearance and excellent processing quality, resistance to cold sweetening, common scab and Fusarium dry rot. Weaknesses include susceptibility to foliar and tuber late blight and susceptibility to metribuzin herbicide injury. Allelic patterns of five SSR markers have shown that Owyhee Russet has a distinctive DNA genetic fingerprint from its russet type reference varieties which are Ranger Russet, Russet Burbank, and Russet Norkotah

Exposure-Based Cash-Flow-At-Risk for Value-Creating Risk Management Under Macroeconomic Uncertainty

A strategically minded CFO will realize that strategic corporate risk management is about finding the right balance between risk prevention and proactive value generation. Efficient risk and performance management requires adequate assessment of risk and risk exposures on the one hand and performance on the other. Properly designed, a risk measure should provide information on to what extend the firm's performance is at risk, what is causing that risk, the relative importance of non-value-adding and value-adding risk, and the possibilities to use risk management to reduce total risk. In this chapter, we present an approach exposure-based cash-flow-at-risk to calculating a firm's downside risk conditional on the firm's exposure to non-value-adding macroeconomic and market risk and to analyzing corporate performance adjusted for the impact of non-value-adding risk

COMPUTER-CONTROLLED GAS CHROMATOGRAPH CAPABLE OF ''REAL-TIME'' READOUT OF HIGH-PRECISION DATA.

A gas chromatograph has been assembled which provides computer control of sample injection, column temperature, and flow rate, plus direct computer readout of inlet pressure, mass flow rate, and detector response. Data processing yields, in real-time, a standard deviation of less than 0.05% in retention time, which is comparable to previous results obtained using an off-line computer. However, corrected retention volumes determined in real-time had a standard deviation of about 0.4% which reflected primarily the uncertainty in flow measurement

Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance

Chemotherapy remains the standard of care for most cancers worldwide, however development of chemoresistance due to the presence of the drug-effluxing ATP binding cassette (ABC) transporters remains a significant problem. The development of safe and effective means to overcome chemoresistance is critical for achieving durable remissions in many cancer patients. We have investigated the energetic demands of ABC transporters in the context of the metabolic adaptations of chemoresistant cancer cells. Here we show that ABC transporters use mitochondrial-derived ATP as a source of energy to efflux drugs out of cancer cells. We further demonstrate that the loss of methylation-controlled J protein (MCJ) (also named DnaJC15), an endogenous negative regulator of mitochondrial respiration, in chemoresistant cancer cells boosts their ability to produce ATP from mitochondria and fuel ABC transporters. We have developed MCJ mimetics that can attenuate mitochondrial respiration and safely overcome chemoresistance in vitro and in vivo. Administration of MCJ mimetics in combination with standard chemotherapeutic drugs could therefore become an alternative strategy for treatment of multiple cancers